In the phase 1 trial evaluation of venetoclax monotherapy in relapsed/refractory MM patients, BCL-2, BCL-XL, and MCL-1 gene expression was quantified by droplet digital polymerase chain reaction (PCR) (n = 44). This evidence concerns the gene BCL2L1 and Miyoshi myopathy.